Advanced Medullary Thyroid Cancer With Ret Mutation Therapeutics
1. Caprelsa patent expiration
Treatment: For use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642608 | GENZYME CORP | Quinazoline derivatives as VEGF inhibitors |
Feb, 2022
(3 years ago) | |
| USRE42353 | GENZYME CORP | Quinazoline derivatives and pharmaceutical compositions containing them |
Sep, 2017
(8 years ago) | |
| US7173038 | GENZYME CORP | Quinazoline derivatives as VEGF inhibitors |
Aug, 2021
(4 years ago) | |
| US8067427 | GENZYME CORP | Pharmaceutical compositions comprising ZD6474 |
Aug, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Apr 06, 2018 |
| Orphan Drug Exclusivity(ODE-9) | Apr 06, 2018 |
Drugs and Companies using VANDETANIB ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 06 April, 2011
Dosage: TABLET
More Information on Dosage
CAPRELSA family patents
